PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.539
https://www.valueinhealthjournal.com/article/S1098-3015(19)32917-1/fulltext
Title :
PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32917-1&doi=10.1016/j.jval.2019.09.539
First page :
Section Title :
Open access? :
No
Section Order :
10460